{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:55:00Z","timestamp":1781513700638,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This study aimed to investigate the histopathological and biochemical neuroprotective effects of IL-1 receptor antagonist (anakinra) administration in an asphyxia-induced cardiac arrest model. A total of 24 Wistar albino rats were randomized into three groups: control, sham (cardiac arrest\u2009+\u2009saline), and anakinra (cardiac arrest\u2009+\u200950\u00a0mg\/kg anakinra). Brain tissues were evaluated using a six-parameter semi-quantitative histopathological scoring system, and the composite damage score (CDS) was calculated (0\u201312). Levels of antioxidant and oxidative markers SOD, CAT, GSH, and MDA were analyzed spectrophotometrically. In the anakinra-treated group, neuronal degeneration, gliosis, and neuropil edema levels were significantly lower compared to the sham group (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01 for all). Although vascular congestion and perivascular edema were observed to be lower in the anakinra group, this reduction was not statistically significant in score analyses compared to the sham group (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&gt;\u20090.05). No significant difference was found between the groups in terms of PMNL infiltration. In biochemical analyses, SOD, CAT, and GSH levels were found to be significantly higher in the anakinra group compared to both the sham and control groups (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), while MDA levels were significantly lower (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). These findings indicate that anakinra reduces oxidative stress and significantly alleviates neurohistopathological damage in the experimental model. Anakinra administration significantly reduced short-term hypoxic-ischemic brain damage following cardiac arrest, both in terms of histopathological and oxidative stress parameters. The findings suggest that targeting the IL-1-mediated inflammatory response could be an important neuroprotective approach; however, further studies are needed regarding dose, timing of administration, and long-term neurological function.\n                  <\/jats:p>","DOI":"10.1007\/s00210-026-05135-w","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T09:35:56Z","timestamp":1773653756000},"page":"12573-12584","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neuroprotective effects of Interleukin-1 receptor antagonism after cardiac arrest: an experimental rat study"],"prefix":"10.1007","volume":"399","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3907-0888","authenticated-orcid":false,"given":"Bilal","family":"Arslan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7590-7999","authenticated-orcid":false,"given":"Fatma Ayaz","family":"Yal\u0131nk\u0131l\u0131\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3105-2749","authenticated-orcid":false,"given":"Adnan","family":"Erse\u00e7kin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1565-8062","authenticated-orcid":false,"given":"Burhan","family":"Beger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5244-706X","authenticated-orcid":false,"given":"Bilal","family":"Acar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4434-1670","authenticated-orcid":false,"given":"Utku","family":"Batu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2025-4983","authenticated-orcid":false,"given":"Mehmet Mehdi","family":"O\u011fuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2702-5905","authenticated-orcid":false,"given":"Abdulaziz","family":"Yal\u0131nk\u0131l\u0131\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4932-8758","authenticated-orcid":false,"given":"Orhan","family":"Beger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3263-4633","authenticated-orcid":false,"given":"Mehmet Zeki","family":"Erdem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5598-2601","authenticated-orcid":false,"given":"Halit","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"issue":"8","key":"5135_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/nri1664","volume":"5","author":"SM Allan","year":"2005","unstructured":"Allan SM, Tyrrell PJ, Rothwell NJ (2005) Interleukin-1 and neuronal injury. Nat Rev Immunol 5(8):629\u2013640","journal-title":"Nat Rev Immunol"},{"key":"5135_CR2","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.expneurol.2015.05.024","volume":"275","author":"PJ Bergold","year":"2016","unstructured":"Bergold PJ (2016) Treatment of traumatic brain injury with anti-inflammatory drugs. Exp Neurol 275:367\u2013380","journal-title":"Exp Neurol"},{"issue":"5","key":"5135_CR3","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.bbi.2010.01.011","volume":"24","author":"SJ Campbell","year":"2010","unstructured":"Campbell SJ, Meier U, Mardiguian S, Jiang Y, Littleton ET, Bristow A, Anthony DC (2010) Sickness behaviour is induced by a peripheral CXC-chemokine also expressed in multiple sclerosis and EAE. Brain Behav Immun 24(5):738\u2013746","journal-title":"Brain Behav Immun"},{"issue":"9","key":"5135_CR4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.040474","volume":"14","author":"N Chaparro\u2010Cabanillas","year":"2025","unstructured":"Chaparro\u2010Cabanillas N, Aliena\u2010Valero A, Pedragosa J, Pedrosa L, Honores M, Rossinyol\u2010Boladeres M, Planas AM (2025) Protective effects of \u0131nterleukin\u20101 \u0131nhibition with anakinra in mouse models of \u0131schemic stroke with and without reperfusion. J Am Heart Assoc 14(9):e040474","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"5135_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.jcbfm.9600537","volume":"28","author":"SR Clark","year":"2008","unstructured":"Clark SR, McMahon CJ, Gueorguieva I, Rowland M, Scarth S, Georgiou R, Rothwell NJ (2008) Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations. J Cereb Blood Flow Metab 28(2):387\u2013394","journal-title":"J Cereb Blood Flow Metab"},{"key":"5135_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2024.156536","volume":"176","author":"JT Dekay","year":"2024","unstructured":"Dekay JT, Chepurko E, Chepurko V, Knudsen L, Lord C, Searight M, Ryzhov S (2024) Delayed CCL23 response is associated with poor outcomes after cardiac arrest. Cytokine 176:156536","journal-title":"Cytokine"},{"issue":"2","key":"5135_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/jcbfm.2010.103","volume":"31","author":"J Galea","year":"2011","unstructured":"Galea J, Ogungbenro K, Hulme S, Greenhalgh A, Aarons L, Scarth S, Tyrrell P (2011) Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study. J Cereb Blood Flow Metab 31(2):439\u2013447","journal-title":"J Cereb Blood Flow Metab"},{"key":"5135_CR8","doi-asserted-by":"publisher","DOI":"10.5505\/tjtes.2015.57894","author":"A Hasturk","year":"2015","unstructured":"Hasturk A, Yilmaz E, Turkoglu E, Kertmen H, Horasanli B, Hayirli N, Evirgen O (2015) Therapeutic evaluation of interleukin 1-beta antagonist anakinra against traumatic brain injury in rats. Turk J Trauma Emerg Surg. https:\/\/doi.org\/10.5505\/tjtes.2015.57894","journal-title":"Turk J Trauma Emerg Surg"},{"issue":"3","key":"5135_CR9","first-page":"87","volume":"16","author":"E Hirik","year":"2018","unstructured":"Hirik E, Suleyman B, Mammadov R, Yapanoglu T, Cimen FK, Cetin N, Kurt N (2018) Effect of anakinra, an interleukin one beta antagonist, on oxidative testicular damage induced in rats with ischemia reperfusion. Rev Int Androl 16(3):87\u201394","journal-title":"Rev Int Androl"},{"issue":"16_suppl_2","key":"5135_CR10","doi-asserted-by":"publisher","first-page":"S673","DOI":"10.1161\/CIR.0000000000001375","volume":"152","author":"KG Hirsch","year":"2025","unstructured":"Hirsch KG, Amorim E, Coppler PJ, Drennan IR, Elliott A, Gordon AJ, Rittenberger JC (2025) Part 11: post\u2013cardiac arrest care: 2025 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 152(16_suppl_2):S673\u2013S718","journal-title":"Circulation"},{"issue":"6","key":"5135_CR11","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1007\/s13311-023-01421-0","volume":"20","author":"C Lindblad","year":"2023","unstructured":"Lindblad C, Rostami E, Helmy A (2023) Interleukin-1 receptor antagonist as therapy for traumatic brain injury. Neurotherapeutics 20(6):1508\u20131528","journal-title":"Neurotherapeutics"},{"issue":"2","key":"5135_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.5853\/jos.2023.04329","volume":"26","author":"S Marasini","year":"2024","unstructured":"Marasini S, Jia X (2024) Neuroprotective approaches for brain injury after cardiac arrest: current trends and prospective avenues. J Stroke 26(2):203\u2013230","journal-title":"J Stroke"},{"key":"5135_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.resuscitation.2021.02.012","volume":"161","author":"JP Nolan","year":"2021","unstructured":"Nolan JP, Sandroni C, B\u00f6ttiger BW, Cariou A, Cronberg T, Friberg H, Soar J (2021) European resuscitation council and European society of intensive care medicine guidelines 2021: post-resuscitation care. Resuscitation 161:220\u2013269","journal-title":"Resuscitation"},{"issue":"12","key":"5135_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126531","volume":"22","author":"M Pariano","year":"2021","unstructured":"Pariano M, Pieroni S, De Luca A, Iannitti RG, Borghi M, Puccetti M, Romani L (2021) Anakinra activates superoxide dismutase 2 to mitigate inflammasome activity. Int J Mol Sci 22(12):6531","journal-title":"Int J Mol Sci"},{"issue":"3","key":"5135_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nrneurol.2017.13","volume":"13","author":"DW Simon","year":"2017","unstructured":"Simon DW, McGeachy MJ, Bay\u0131r H, Clark RS, Loane DJ, Kochanek PM (2017) The far-reaching scope of neuroinflammation after traumatic brain injury. Nat Rev Neurol 13(3):171\u2013191","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"5135_CR16","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1161\/STROKEAHA.115.010001","volume":"47","author":"OA Sobowale","year":"2016","unstructured":"Sobowale OA, Parry-Jones AR, Smith CJ, Tyrrell PJ, Rothwell NJ, Allan SM (2016) Interleukin-1 in stroke: from bench to bedside. Stroke 47(8):2160\u20132167","journal-title":"Stroke"},{"issue":"5","key":"5135_CR17","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018657","volume":"10","author":"T Uray","year":"2021","unstructured":"Uray T, Dezfulian C, Palmer AA, Miner KM, Leak RK, Stezoski JP, Drabek T (2021) Cardiac arrest induced by asphyxia versus ventricular fibrillation elicits comparable early changes in cytokine levels in the rat brain, heart, and serum. J Am Heart Assoc 10(5):e018657","journal-title":"J Am Heart Assoc"},{"key":"5135_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.1087725","volume":"16","author":"S Yu","year":"2023","unstructured":"Yu S, Wu C, Zhu Y, Diao M, Hu W (2023) Rat model of asphyxia-induced cardiac arrest and resuscitation. Front Neurosci 16:1087725","journal-title":"Front Neurosci"},{"key":"5135_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.855701","volume":"13","author":"RZ Zheng","year":"2022","unstructured":"Zheng RZ, Lee KY, Qi ZX, Wang Z, Xu ZY, Wu XH, Mao Y (2022) Neuroinflammation following traumatic brain injury: take it seriously or not. Front Immunol 13:855701","journal-title":"Front Immunol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05135-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05135-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05135-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:19:26Z","timestamp":1781511566000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05135-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["5135"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05135-w","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Van Y\u00fcz\u00fcnc\u00fc Y\u0131l University Experimental Animals Local Ethics Committee (Approval date: 25\/12\/2025, No: 2025\/13\u201319).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}